Carmel Capital Partners LLC Buys 4,115 Shares of IQVIA Holdings Inc. $IQV

Carmel Capital Partners LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 38.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,878 shares of the medical research company’s stock after buying an additional 4,115 shares during the quarter. IQVIA makes up 0.8% of Carmel Capital Partners LLC’s holdings, making the stock its 29th biggest holding. Carmel Capital Partners LLC’s holdings in IQVIA were worth $2,345,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares during the period. Nordea Investment Management AB lifted its holdings in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the period. American Century Companies Inc. lifted its holdings in shares of IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after purchasing an additional 304,258 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after purchasing an additional 40,699 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.6%

IQV opened at $204.51 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.21. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $34.77 billion, a P/E ratio of 29.60, a price-to-earnings-growth ratio of 2.26 and a beta of 1.32. The company has a fifty day moving average price of $191.41 and a two-hundred day moving average price of $169.23.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the firm posted $2.64 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on IQV shares. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Mizuho boosted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Evercore ISI boosted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $234.57.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.